You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Biologics Targeting the IL-23/IL-17 Pathway in Psoriatic Disease: Treating Beyond the Skin

  • Authors: Laura Savage, MBChB, BSc(Hons), MRCP(UK), MRCP (Dermatology), PhD; Andrew Blauvelt, MD, MBA; Dennis McGonagle, FRCPI, PhD
  • CME Released: 11/14/2022
  • Valid for credit through: 11/14/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of dermatologists, rheumatologists, and primary care physicians.

The goal of this activity is for learners to be better able to highlight the role of dermatologists in early identification of psoriatic arthritis (PsA) and the management of patients with psoriasis who develop PsA.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Transition of psoriasis to PsA
    • Key clinical data for interleukin (IL)-23/IL-17 inhibitors in psoriatic disease


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Laura Savage, MBChB BSc(Hons) MRCP(UK) MRCP (Dermatology) PhD

    Consultant Dermatologist
    University of Leeds
    Leeds Teaching Hospitals NHS Trust
    Clinical Research Fellow and Specialist Registrar
    Leeds Centre for Dermatology
    Leeds, United Kingdom

    Disclosures

    Laura Savage, MBChB, BSc(Hons), MRCP(UK), MRCP (Dermatology), PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Eli Lilly and Company; Janssen; Leo Pharma; Novartis; UCB
    Speaker or member of speakers bureau for: AbbVie; Almirall; Aspire Pharma; Janssen; Leo Pharma; Novartis; Sanofi; UCB

Panelists

  • Andrew Blauvelt, MD, MBA

    Professor of Dermatology
    Oregon Health & Science University
    President of the Oregon Medical Research Center
    Portland, Oregon, United States

    Disclosures

    Andrew Blauvelt, MD, MBA, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Abcentra; Aligos Therapeutics; Almirall; Arcutis Biotherapeutics; Arena Pharmaceuticals; Aslan Pharma; Athenex; Boehringer Ingelheim; Bristol Myers Squibb; Dermavant Sciences Inc.; EcoRI; Eli Lilly and Company; Evommune, Inc.; Forte; Galderma; Incyte; Janssen; Landos Biopharma; Leo Pharma; Novartis; Pfizer; RAPT Therapeutics; Regeneron Pharmaceuticals; Sanofi Genzyme; Sun Pharmaceutical Industries Ltd.; UCB; Vibliome Therapeutics; Xenco Medical
    Speaker or member of speakers bureau for: AbbVie; UCB
    Research funding from: AbbVie; Amgen; Arcutis Biotherapeutics; Athenex; Boehringer Ingelheim; Bristol Myers Squibb; Dermavant Sciences Inc.; Eli Lilly and Company; Galderma; Incyte; Janssen; Leo Pharma; Novartis; Pfizer; Regeneron Pharmaceuticals; Sun Pharmaceutical Industries Ltd.; UCB

  • Dennis McGonagle, FRCPI, PhD

    Professor of Investigative Rheumatology
    NIHR funded Academic Unit for the Musculoskeletal Diseases
    Leeds Teaching Hospitals NHS Trust
    Leeds, United Kingdom

    Disclosures

    Dennis McGonagle, FRCPI, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Bristol Myers Squibb; Celgene; Eli Lilly and Company; Janssen; Novartis; Pfizer; UCB
    Speaker or member of speakers bureau for: AbbVie; Bristol Myers Squibb; Celgene; Eli Lilly and Company; Janssen; Novartis; Pfizer; UCB
    Research funding from: AbbVie; Bristol Myers Squibb; Eli Lilly and Company; Janssen; Novartis; Pfizer; UCB

Editor

  • Shanthi Voorn, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Shanthi Voorn, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Biologics Targeting the IL-23/IL-17 Pathway in Psoriatic Disease: Treating Beyond the Skin

Authors: Laura Savage, MBChB, BSc(Hons), MRCP(UK), MRCP (Dermatology), PhD; Andrew Blauvelt, MD, MBA; Dennis McGonagle, FRCPI, PhDFaculty and Disclosures

CME Released: 11/14/2022

Valid for credit through: 11/14/2023

processing....

Deutscher Expertenkommentar

Dieser Kommentar ist Teil einer umfangreicheren Fortbildungsmaßnahme. Gehen Sie für den Zugriff auf alle zugehörigen Fortbildungsinhalte nach Ihrer Teilnahme bitte zu Biologics Targeting the IL-23/IL-17 Pathway in Psoriatic Disease: Treating Beyond the Skin.

 
« Return to: Biologics Targeting the IL-23/IL-17 Pathway in Psoriatic Disease: Treating Beyond the Skin